Revvity has launched its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.
The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity Signals Notebook, VitroVivo and Inventa applications into a single, robust solution that supports the entire drug development process, from early research and in vitro testing and safety to early development as well as specialty chemicals new product development.
“With the Signals Research Suite, scientists can go further in their work with one solution that encapsulates the products they already trust and avoids the complexities and inefficiencies of a piecemeal, application-centric ecosystem,” said Kevin Willoe, Senior vice president and general manager of the newly-branded Revvity Signals Software.
